Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3035-3039

  DiCenzo, Robert ^a,b,d   Peterson, Derick R ^b   Cruttenden, Kim ^b   Mariuz, Peter ^b   Rezk, Naser L ^c   Hochreiter, Jill ^a   Gelbard, Harris ^b   Schifitto, Giovanni ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACICLOVIR; AMITRIPTYLINE; ATAZANAVIR; ATORVASTATIN; COTRIMOXAZOLE; DIDANOSINE; EMTRICITABINE; ENFUVIRTIDE; ESTRADIOL; FENOFIBRATE; GABAPENTIN; LAMIVUDINE; MEDROXYPROGESTERONE; MINOCYCLINE; PAROXETINE; PRAVASTATIN; RANITIDINE; RITONAVIR; ROSIGLITAZONE; SALBUTAMOL; SAQUINAVIR; SPIRONOLACTONE; STAVUDINE; TENOFOVIR; TRAZODONE; UNINDEXED DRUG; VALPROIC ACID; VANCOMYCIN; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; FEMALE; GEOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEAL; NAUSEA; PRIORITY JOURNAL; STEADY STATE;

ADULT; ANTICONVULSANTS; COGNITION DISORDERS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; VALPROIC ACID;

EID: 50949095973     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00194-08     Document Type: Article

References (25)

1. Acosta, E. P., J. G. Gerber, and the Adult Pharmacology Committee of the AIDS Clinical Trials Group. 2002. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res. Hum. Retrovir. 18:825-834.
2. Ances, B. M., and R. J. Ellis. 2007. Dementia and neurocognitive disorders due to HIV-1 infection. Semin. Neurol. 27:86-92.
3. Böcker, R., C.-J. Estler, and D. Ludewig-Sandig. 1991. Evaluation of the hepatotoxic potential of minocycline. Antimicrob. Agents Chemother. 35:1434-1436.
4. Burger, D. M., P. Hugen, P. Reiss, I. Gyssens, M. Schneider, F. Kroon, G. Schreij, K. Brinkman, C. Richter, J. Prins, R. Aarnoutse, and J. Lange. 2003. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 17:1157-1165.
5. Cole, J. J., B. G. Charles, and P. J. Ravenscroft. 1980. Interaction of cimetidine with tetracycline absorption. Lancet ii:536.
6. d'Arminio Monforte, A., P. Cinque, A. Mocroft, F. D. Goebel, F. Antunes, C. Katlama, U. S. Justesen, S. Vella, O. Kirk, and J. Lundgren for the EuroSIDA Study Group. 2004. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann. Neurol. 55:320-328.
7. DiCenzo, R., D. Peterson, K. Cruttenden, G. Morse, G. Riggs, H. Gelbard, and G. Schifitto. 2004. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentration in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 48:4328-4331.
8. Dou, H., K. Birusingh, J. Faraci, S. Gorantla, L. Y. Poluektova, S. B. Maggirwar, S. Dewhurst, H. A. Gelbard, and H. E. Gendelman. 2003. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J. Neurosci. 23:9162-9170.
9. Fletcher, C. V., P. L. Anderson, T. N. Kakuda, T. W. Schacker, K. Henry, C. R. Gross, and R. C. Brundage. 2002. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 16:551-560.
10. Flexner, C., and S. Piscitelli. 2002. Concentration-targeted therapy and the future of HIV management. AIDS 16:S1-S3.
11. Frerichs, V. A., R. DiFrancesco, and G. D. Morse. 2003. Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry. J. Chromatogr. 787:393-403.
12. Kawai, M., A. Honda, H. Yoshida, M. Goto, and T. Shimokata. 1992. Possible theophylline-minocycline interaction. Ann. Pharmacother. 25:1300-1301.
13. Raffanti, S., and D. Haas. 2001. Antimicrobial agents: antiviral agents, p. 1364-1373. In L. S. Goodman, L. E. Limbird, P. B. Milinoff, R. W. Ruddon, and A. G. Gilman (ed.), The pharmacological basis of therapeutics, 9th ed. McGraw-Hill, New York, NY.
14. Rezk, N. L., R. R. Tidwell, and A. D. M. Kashuba. 2004. High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. J. Chromatogr. 805:241-247.
15. Sacktor, N., M. P. McDermott, K. Marder, G. Schifitto, O. A. Selnes, J. C. McArthur, Y. Stern, S. Albert, D. Palumbo, K. Kieburtz, J. A. De Marcaida, B. Cohen, and L. Epstein. 2002. HIV-associated cognitive impairment before and after the advent of combination therapy. J. Neurovirol. 8:136-142.
16. Schifitto, G., D. R. Peterson, J. Zhong, H. Ni, K. Cruttenden, M. D. Gaugh, H. E. Gendelman, M. Boska, and H. Gelbard. 2006. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 66:919-921.
17. Shapiro, L. E., S. R. Knowles, and N. H. Shear. 1997. Comparative safety of tetracycline, minocycline and doxycycline. Arch. Dermatol. 133:1224-1230.
18. Sheehan, N. L., M.-J. Brouillette, M.-S. Delisle, and J. Allan. 2006. Possible interaction between lopinavir/ritonavir and valproic acid exacerbates bipolar disorder. Ann. Pharmacother. 40:147-150.
19. Thomas, M., W. D. Le, and J. Jankovic. 2003. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin. Neuropharmacol. 26:18-23.
20. Ueno, K., K. Miyai, and K. Bito. 1991. Interaction between theophylline and minocycline. Jpn. J. Ther. Drug Monit. 7:140-143.
21. Wang, X., S. Zhu, M. Drozda, W. Zhang, I. G. Stavrovskaya, E. Cattaneo, R. J. Ferrante, B. S. Kristal, and R. M. Friedlander. 2003. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl. Acad. Sci. USA 100:10483-10487.
22. Zhanel, G. G., K. Homenuik, A. Noreddin, L. Vercaigne, J. Embil, A. Gin, J. Karlowsky, and D. J. Hoban. 2004. The glycylcyclines: a comparative review with the tetracyclines. Drugs 64:63-88.
23. Zink, M. C., J. Uhrlaub, J. DeWitt, T. Voelker, B. Bullock, J. Mankowski, P. Tarwater, J. Clements, and S. Barber. 2005. Neuroprotective and antihuman immunodeficiency virus activity of minocycline. JAMA 293:2003-2011.
24. Zucchero, F. J., and M. J. Hogan. 1994. Tetracycline - oral contraceptives, p. 8/93.00. In F. J. Zucchero and M. J. Hogan (ed.), Evaluations of drug interactions. Professional Drug Systems, Inc., St. Louis, MO.
25. Zucchero, F. J., and M. J. Hogan. 1994. Digoxin-tetracycline, p. 12/55.00. In F. J. Zucchero and M. J. Hogan (ed.), Evaluations of drug interactions. Professional Drug Systems, Inc., St. Louis, MO.